{"groups":[{"description":"Nivolumab 240 mg Q2W for 8 cycles (16 weeks) followed by Nivolumab 480 mg Q4W for 9 cycles.","id":"FG000","title":"Nivolumab"},{"description":"Placebo IV Q2W for 8 cycles (16 weeks) followed by Placebo IV Q4W for 9 cycles","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant request to discontinue treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant no longer meeting study criteria"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"532"},{"groupId":"FG001","numSubjects":"262"}],"comment":"Started = randomized","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"532"},{"groupId":"FG001","numSubjects":"260"}],"comment":"Completed = Entering the treatment period","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Pre-treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"115"}],"type":"Disease recurrence"},{"reasons":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"8"}],"type":"Study drug toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"9"}],"type":"Adverse event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"5"}],"type":"Participant request to discontinue treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"4"}],"type":"Participant withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Poor/Non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}],"type":"Other reasons"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"532"},{"groupId":"FG001","numSubjects":"260"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"260"},{"groupId":"FG001","numSubjects":"116"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"272"},{"groupId":"FG001","numSubjects":"144"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"}],"preAssignmentDetails":"794 participants were randomized and 792 were treated. The reasons for the 2 participants not being treated were: Participant request to discontinue study treatment (1) and Participant no longer meeting study criteria (1)."}